Symbyax is an antidepressant medicine manufactured by Eli Lilly, and is known generically as a combination of fluoxetine and olanzapine. Symbyax is categorized as a selective serotonin re-uptake inhibitor (SSRI). Used to treat depression, Symbyax was approved for use by the U.S. Food and Drug Administration in 2003.
Pregnant women who use an SSRI antidepressant, such as Symbyax, during pregnancy have been known to give birth to children with life-threatening and serious birth defects. It is believed that there is a strong link between exposure to SSRI antidepressant, like Symbyax, and the development of life-threatening congenital birth defects.
Birth defects linked to Symbyax exposure include, but are not limited to, the following:
If your newborn suffers from a congenital birth defect as a result of exposure in the womb to Symbyax, you may be eligible to receive compensation for unwarranted pain, suffering, and losses. Please know that you are not alone, and that you do not have to be a silent victim.
Our experienced Symbyax lawyers at Carey Danis & Lowe work hard for our clients in fighting for justice in Symbyax lawsuits. For more information about filing a Symbyax lawsuit, contact a pharmaceutical product liability lawyer at Carey Danis & Lowe.
The FDA has categorized Symbyax as a Pregnancy C drug meaning that an increased risk for congenital birth defects when taken during pregnancy cannot be ruled out.
Common Symbyax birth defects include but are not limited to:
Manufacturer: Eli Lilly
FDA Approval: December 24, 2003 for depression caused by bipolar (manic depression)
Generic Availability: N/A
Pregnancy Risk: Category C